The potential health and economic impact of introducing the vaccine candidate VPM1002 to prevent tuberculosis disease in low- and middle-income countries: a modelling study
Overall rollout in LMICs may avert a portion of symptomatic TB cases and TB-associated deaths, and in some countries could be cost-effective/saving, and in some countries could be cost-effective/saving.